Immune checkpoint Inhibitors, specifically anti‐PD‐1 and anti‐PD‐L1 antibodies, have shown improvement in patient outcomes for cancers such as melanoma, lung cancer, and renal cancer. Here, PDCD1 is linked to cancer.